Inovio Pharmaceuticals, Inc. (INO) stock
Close on Nov 17, 2026Market cap $168.54MP/E –Yield –
Earnings
Inovio Pharmaceuticals's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Quarterly results
Revenue and earnings per share from each of Inovio Pharmaceuticals's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Adj. EPS | Source |
|---|---|---|---|---|---|---|
| Q4 FY2026ended Dec 31, 2026 | Mar 11, 2027Expected | – | – | – | – | – |
| Q3 FY2026ended Sep 30, 2026 | Nov 10, 2026after the close | $298.90K | – | -$0.50 | – | Release |
| Q2 FY2026ended Jun 30, 2026 | Aug 12, 2026after the close | – | – | -$0.07 | – | Release |
| Q1 FY2026ended Mar 31, 2026 | May 13, 2026after the close | – | – | -$0.28 | – | Release |
| Q4 FY2025ended Dec 31, 2025 | Mar 12, 2026after the close | – | – | -$0.26 | – | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 10, 2025after the close | – | – | -$0.87 | – | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 12, 2025after the close | – | – | -$0.61 | – | Release |
| Q1 FY2025ended Mar 31, 2025 | May 13, 2025after the close | – | – | -$0.51 | – | Release |
| Q4 FY2024ended Dec 31, 2024 | Mar 18, 2025after the close | – | – | -$0.65 | – | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 14, 2024after the close | – | – | -$0.89 | – | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 8, 2024after the close | $100.76K | -55.4% | -$1.19 | – | Release |
| Q1 FY2024ended Mar 31, 2024 | May 13, 2024after the close | – | – | -$1.31 | – | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 9, 2023after the close | $388.00K | -95.8% | -$0.13 | -$0.09 | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 9, 2023after the close | $226.00K | -71.2% | -$0.13 | – | Release |
| Q1 FY2023ended Mar 31, 2023 | May 10, 2023after the close | $115.00K | -42.2% | -$0.16 | – | Release |
| Q4 FY2022ended Dec 31, 2022 | Mar 1, 2023after the close | $125.00K | – | -$0.22 | – | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 8, 2022after the close | $9.20M | – | -$0.15 | – | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 9, 2022after the close | $784.00K | – | -$0.46 | – | Release |
| Q1 FY2022ended Mar 31, 2022 | May 10, 2022after the close | $199.00K | – | -$0.36 | – | Release |
| Q4 FY2020ended Dec 31, 2020 | Jan 20, 2021after the close | – | – | – | – | Filing |
| Q4 FY2019ended Dec 31, 2019 | Mar 9, 2020before the open | – | – | – | – | Filing |
| Q4 FY2018ended Dec 31, 2018 | Feb 13, 2019after the close | – | – | – | – | Filing |
| Q2 FY2017ended Jun 30, 2017 | Jul 18, 2017after the close | – | – | – | – | Filing |
| Q4 FY2013ended Dec 31, 2013 | Mar 17, 2014during market hours | – | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Current guidance
Inovio Pharmaceuticals's latest outlook for periods it has not reported yet, compared with what it said before
| Metric | Period | Guidance | Before | Change | Given |
|---|---|---|---|---|---|
| operational net cash burn | Q4 FY2026 | $21.00M | – | New | Nov 10, 2026 |
Guidance history
Every forecast Inovio Pharmaceuticals put in an earnings release, newest first
| Given | Metric | Period | Guidance | Change |
|---|---|---|---|---|
| Nov 10, 2026 | operational net cash burn | Q4 FY2026 | $21.00M | New |
| Aug 12, 2026 | operational net cash burn | Q3 FY2026 | $18.00M | New |
| Mar 12, 2026 | operational net cash burn | Q1 FY2026 | $22.00M | New |
| Aug 12, 2025 | operational net cash burn | Q3 FY2025 | $22.00M | New |
| May 13, 2025 | operational net cash burn estimate | Q2 FY2025 | $22.00M | New |
| Mar 18, 2025 | operational net cash burn | Q1 FY2025 | $27.00M | New |
| Nov 14, 2024 | operational net cash burn | Q4 FY2024 | $24.00M | New |
| Aug 8, 2024 | operational net cash burn | Q3 FY2024 | $28.00M | New |
| May 13, 2024 | operational net cash burn | Q2 FY2024 | $30.00M | New |
| Nov 9, 2023 | cash burn estimate | Q4 FY2023 | $26.00M | New |
| Aug 9, 2023 | cash burn | Q3 FY2023 | $34.00M | New |
| May 10, 2023 | cash burn | Q2 FY2023 | $33.00M | New |
| Mar 1, 2023 | cash burn estimate | Q1 FY2023 | $32.00M | New |
| Nov 8, 2022 | cash burn | Q4 FY2022 | $45.00M | New |
| Aug 9, 2022 | cash burn | Q3 FY2022 | $73.00M | New |
Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.
Press releases
Releases Inovio Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Update
- Update
- Update
- Results
- News
- News
- Results
- News
- News
- Results
- Update
- News
- News
See a number that looks wrong?